Breakingviews

Teva exits Mylan mess with $40.5 bln Allergan deal

July 27, 2015

The Israeli pharma firm has been locked in a bitter battle to take over the Dutch drugmaker. Now it has agreed to buy the generic business from Allergan. The swap makes sense. Friendly is far easier than hostile, and the Allergan businesses are just as attractive as Mylan.

Teva’s $40 bln hostile bid puts hope over reality

April 21, 2015

The Israeli drugmaker needs a deal to shore up falling sales. Smaller rival Mylan offers that and oodles of synergies. A tie-up, though, would face antitrust concerns, require high leverage and have to get around a powerful poison pill. No wonder the market is skeptical.

Egypt-Israel energy ties look broken

April 25, 2012

It is hard to believe that Egypt’s termination of a long-term contract to supply gas to Israel is a pure business dispute given the odd timing of the move. In the absence of a resolution Israel faces some difficult months. That’s bad for peace but doesn’t destroy it.

Iran, the day-after problem

September 30, 2009

The drums of war are beating in the Middle East. Proponents of a military strike against Iran’s nuclear facilities have intensified their campaign in recent weeks, arguing the military option is the only way to ensure the country does not build a nuclear weapon.